tration. In a phase 3 trial of patients with metastatic colorectal cancer, the addition of bevacizumab to standard chemotherapy resulted in improved overall and progression-free survival, resulting in its approval as first-line therapy for metastatic colorectal cancer. 3 Despite the increasing use of bevacizumab, its effects on liver regeneration after hepatic resection have not been clarified. Angiogenesis plays a critical role in liver regeneration, as demonstrated by an increase in VEGF mRNA and protein levels after partial hepatectomy in animal models. 4 In addition, blockage of VEGF in animals suppresses hepatic proliferation after partial hepatectomy. 5 Portal vein embolization (PVE) has been shown to induce a regenerative response that mirrors the regeneration that occurs after partial hepatectomy. PVE induces atrophy of the embolized lobe (to be resected) with compensatory hypertrophy of the nonembolized lobe (the future liver remnant, FLR). 6, 7 The degree of liver hypertrophy (DH) after PVE is accurately quantified with computed tomography (CT) liver volumetry.
The aim of this study was to evaluate the effects of chemotherapy with or without bevacizumab on liver regeneration after PVE in the treatment of colorectal liver metastases (CLM) by evaluating changes in the FLR volume and DH after PVE. A secondary aim was to assess the effects of pre-PVE neoadjuvant chemotherapy, with or without bevacizumab, on postoperative outcomes after major liver resection.
MATERIALS AND METHODS
From a prospective hepatobiliary database at the University of Texas M. D. Anderson Cancer Center, 65 consecutive patients who underwent PVE in anticipation of major liver resection for CLM were identified between September 1995 and April 2007. To differentiate the effects of cytotoxic chemotherapy independently from those of bevacizumab, patients were grouped as follows: group A, patients who received chemotherapy with bevacizumab before PVE; group B, patients who received chemotherapy without bevacizumab before PVE; and group C, patients who were not treated with chemotherapy before PVE. All patients in groups A and B received at least three cycles of neoadjuvant chemotherapy as first-line treatment. Patients who had undergone prior liver resection or received multiple lines of chemotherapy before PVE were excluded. The study was conducted under an institutional review board-approved protocol.
PVE was performed as previously described 8, 9 on the basis of volumetry of the anticipated FLR after evaluation by the operating surgeon (E.K.A. or J.N.V.). PVE was indicated when the FLR volume was £ 20% of the estimated total liver volume (TLV) in patients with normal liver, £ 30% in patients with fibrosis or severe liver injury. 10, 11 Embolization of segment 4 was performed when an extended right hepatectomy was planned on the basis of tumor location.
The FLR volume was measured directly by threedimensional CT volumetry as described previously. 12 14, 15 The ratio between FLR volume and TLV was defined as the standardized FLR (sFLR). The absolute difference between the sFLR before and after PVE was defined as DH. CT liver volumetry was performed before and a median of 4 weeks (range, 2-10 weeks) after PVE to assess changes in sFLR and DH.
Perioperative morbidity was reported according to the classification proposed by Dindo et al. 16 Grade I and II complications were defined as minor, and grade III and IV complications as major. Postoperative mortality was defined as any death within 90 days after surgery or within the hospital stay during which the surgery was performed. Hepatic dysfunction was defined as a peak postoperative bilirubin level greater than 3 mg/dL 17 or a prothrombin time longer than 18 seconds. 18 Hepatic insufficiency was defined as a peak postoperative bilirubin level>7 mg/dL. 19 Statistical analysis was performed with SPSS version 12 (SPSS, Chicago, IL). Continuous data were expressed as mean ± standard deviation (95% confidence interval) unless otherwise indicated and compared by the Mann-Whitney U-test, the t-test, or the Kruskal-Wallis test, as appropriate. Dichotomous variables were compared by means of the v 2 test or Fisher's exact test, as appropriate. The relationship between liver regeneration and clinical outcome was investigated by the sFLR after PVE and the DH. Statistical significance was defined as P < .05.
RESULTS
Clinicopathological features of the 65 patients studied are shown in Table 1 . Oxaliplatin-based chemotherapy with bevacizumab was administered before PVE in 26 patients (group A) and without bevacizumab in 17 patients (group B, Fig. 1 ). Twenty-two patients underwent PVE without prior chemotherapy (group C). Group A patients received a median of six cycles of chemotherapy (range, 3-20 cycles), which was discontinued a median of 7.4 weeks (range, 2-35 weeks) before PVE. Group B patients received a median of five cycles of chemotherapy (range, 3-23 cycles), which was discontinued a median of 7.2 weeks (range, 2-20 weeks) before PVE. In group A patients, the last cycle of chemotherapy was usually given without bevacizumab; thus, the median time interval between the last dosage of bevacizumab and PVE was 7.9 weeks (range, 3-36 weeks). Four patients in group A and four in group B received chemotherapy during the interval between PVE and hepatic surgery; none of them received bevacizumab during the interval time.
Regeneration After PVE (FLR and DH)
Liver volumetry data are shown in Table 2 . The absolute FLR volume significantly increased after a median of 4 weeks (range, 2-10 weeks) after PVE in all groups. The gain in absolute FLR volume after PVE was neither affected by chemotherapy before PVE nor by the addition of bevacizumab (P = .35, Fig. 2) .
Similarly, neither chemotherapy nor bevacizumab affected the increase in sFLR after PVE (P = .56). The sFLR in patients treated with bevacizumab (group A) increased from a mean of 21% to 30%. In patients who received chemotherapy without bevacizumab (group B), the sFLR increased from a mean of 22% to 28%. Patients who did not receive chemotherapy (group C) had an increase in mean sFLR from 22% to 32%.
There was no statistically significant difference in DH among the patient groups (P = .15). The mean values of DH after PVE for groups A, B, and C were 9%, 7%, and 10%, respectively. The mean DH for all patients who received chemotherapy before PVE (groups A and B) was not significantly different from the DH of patients who did not receive chemotherapy, 
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group C (8%, groups A and B vs. 10%, group C, P = .11). The duration of pre-PVE chemotherapy did not affect liver regeneration, as there was no correlation between DH and number of cycles of pre-PVE chemotherapy, with or without bevacizumab (P = .75). Twenty-three patients received six or more cycles of chemotherapy before PVE, and 20 patients received fewer than six cycles. Patients treated with six or more cycles had a DH of 9% versus a DH of 8.8% in patients treated with fewer than six cycles (P = .5). Figure 3 represents the correlation between the chemotherapy-free or bevacizumab-free time before PVE and DH in group A and group B. In group A the time interval between the last dose of bevacizumab and PVE was £ 8 weeks in 12 patients and >8 weeks in 14 patients. The DH was higher in patients who had a > 8-weeks interval between bevacizumab and PVE, but this difference was not statistically significant (10.3% vs. 7%; P = .11). In group B, the difference in DH was not statistically significant between patients with a >7-weeks interval (9 patients) and those with a £ 7-weeks interval (8 patients) between chemotherapy and PVE (7.5% vs. 6.3%, P = .9).
Resectability and Outcome
A total of 48 (74%) of 65 patients underwent extended right or right hepatectomy after PVE. Seventeen patients (26%) did not undergo hepatic resection after PVE because of extrahepatic (n = 8 patients) or intrahepatic (n = 2) progression of disease, inadequate hepatic regeneration (n = 4), or clinically important medical comorbidities (n = 3). Among patients with inadequate hepatic regeneration after PVE, one had received preoperative chemotherapy with bevacizumab and two without bevacizumab, and one had received no chemotherapy. The surgical procedures performed are summarized in Table 3 . Of note, 11 of 36 patients who underwent extended right hepatectomy and one of 12 who had right hepatectomy also had a synchronous extrahepatic procedure, including diaphragm resection, vena cava resection, common bile duct resection, lung wedge resection, and bowel resection. After a median follow-up of 13 months, the median survival for the resected patients with or without chemotherapy was 35 vs. 55 months, respectively (P = .2). No statistically significant differences in postoperative hepatic dysfunction, morbidity, and mortality were observed among the patient groups. Median hospital stay after hepatic resection for all resected patients was 7 days (range, 5-52 days). No statistically significant difference between patients who had undergone chemotherapy with or without bevacizumab was observed (7 vs. 8 days, respectively; P = .89).
In the group without chemotherapy, postoperative complications occurred in eight patients (50%). Grade II complications in five patients included selflimited biliary fistula (n = 2) and hepatic dysfunction (n = 3), and pneumonia (n = 2). Two patients experienced grade IIIa complications, including bile leak/biloma (n = 1) and intra-abdominal fluid collection and hepatic dysfunction (n = 1). One patient underwent reoperation for small bowel perforation (grade IIIb complication). Nobody in the withoutchemotherapy group died.
In the chemotherapy group, hepatic resection was performed in 32 patients (74%) ( Table 3) . Twentytwo extended right and 10 right hepatectomies were performed. Postoperative complications occurred in 15 patients (47%). One patient experienced grade I complication (high serum potassium level); grade II complications in four patients included hepatic dysfunction (n = 2), atrial fibrillation (n = 1), and prolonged ileus (n = 1). Eight patients experienced grade IIIa complications, including hepatic dysfunction (n = 2), hepatic insufficiency (n = 3), and intraabdominal fluid collection (n = 3). Two patients died (90-day mortality) of hepatic insufficiency and multiorgan failure (grade V). In summary, a total of 13 patients developed hepatic dysfunction, 5 of whom experienced hepatic insufficiency, and 2 of these died from liver failure ( Table 3) .
DISCUSSION
The addition of bevacizumab to standard chemotherapy has resulted in improved overall and progression-free survival rates in patients with metastatic colorectal cancer. 3 However, the critical role of VEGF in liver regeneration has raised concerns regarding impaired liver regeneration after preoperative administration of bevacizumab. In this study, we analyzed the effects of bevacizumab and chemotherapy administered to patients before PVE in anticipation of major liver resection for CLM and found that chemotherapy with bevacizumab did not impair liver regeneration after PVE. We also found that the incidence of postoperative complications and 90-day mortality were not increased with the addition of bevacizumab to oxaliplatin-based chemotherapy. These findings support previous studies on the safety of bevacizumab before hepatectomy for CLM. [20] [21] [22] To our knowledge, this is the first study to analyze the effects of bevacizumab on liver regeneration in humans. Preclinical data in animal models are lacking because bevacizumab specifically recognizes the human form of VEGF, not murine VEGF. However, animal studies have demonstrated that liver regeneration depends on VEGF and angiogenesis. 23 In rats, exogenous VEGF after partial hepatectomy stimulates liver regeneration by inducing proliferation of hepatocytes and liver sinusoidal endothelial cells, whereas anti-VEGF therapy suppresses hepatic proliferation. In the current study, the DH of the FLR after PVE was not affected by bevacizumab. The likely explanation for the discrepancy between our clinical study and previous animal studies is the timing of bevacizumab administration. In murine models, angiogenesis and hepatocyte proliferation were delayed when anti-VEGF was administered 0 to 96 hours after partial hepatectomy. In the present report, patients underwent PVE a median of 8 weeks after the last dose of bevacizumab. A shorter time interval between bevacizumab administration and PVE could interfere with angiogenesis and liver regeneration. This study supports the recommendation to stop bevacizumab 6 to 8 weeks before any intervention that causes insult to the liver, such as PVE or hepatic resection, 20, 24 although the interval time of discontinuation has not been standardized and still need to be investigated.
We chose to study the effects of bevacizumab on liver regeneration in patients who underwent PVE before major liver resection because they represent a relatively uniform group of patients who have not undergone previous liver resection. In addition, they underwent systematic analysis of liver volumes before and after PVE to assess changes in sFLR and DH. PVE has been shown to mimic the effects of liver regeneration after resection. 6, 7 PVE results in apoptosis in the embolized lobes with compensatory proliferation of the nonembolized lobe. In a rat model of portal vein ligation, the ligated lobes atrophied to 10% of their original weight within 2 weeks, while the nonoccluded lobes hypertrophied to reconstitute the original liver mass. 6 In patients with CLM, PVE is frequently part of a multimodal treatment that includes preoperative chemotherapy. Covey et al. 25 found that liver growth was similar between patients treated with or without chemotherapy after PVE. In this study, we found that treatment with chemotherapy, with or without bevacizumab, did not affect the gains in sFLR, which ranged from a mean of 21% to 22% before PVE to 28% to 32% after PVE. Previously, we showed that in patients without underlying liver disease, the minimum sFLR for safe major hepatectomy was 20%. In addition, a DH of at least 5% has been shown to be predictive of a decreased risk of postoperative hepatic dysfunction. 26 In this series, the mean DH ranged from 7% to 10% and was not affected by treatment with chemotherapy or bevacizumab. The rate of postoperative hepatic dysfunction was similar among patient groups and ranged between 25% to 31%.
The second major finding of this study was that postoperative morbidity and mortality rates were not higher in patients treated with chemotherapy, with or without bevacizumab. This is in agreement with previous studies showing that perioperative treatment with bevacizumab does not increase morbidity after hepatectomy for CLM. 20, 22 However, large randomized trials on bevacizumab for stage IV colorectal cancer have demonstrated rare but potentially fatal risks of gastrointestinal perforation and arterial thrombotic events when surgery was performed while patients received bevacizumab treatment. In a pooled analysis, wound healing complications after major surgery occurred in 13% of bevacizumab-treated patients, compared with 3.4% of control patients. 27 These data highlight the importance of stopping bevacizumab 6 to 8 weeks before performing elective hepatic resection or PVE.
In this series, patients received oxaliplatin-based chemotherapy without increase in postoperative morbidity and mortality, as previously shown in a large multi-institutional study. 28 However, oxaliplatin has been associated with hepatic sinusoidal dilatation. 28, 29 In a previous clinical study, we showed that bevacizumab reduces the incidence and severity of oxaliplatin-related hepatic sinusoidal dilation 21 ; this finding suggests a benefit for the use of bevacizumab-containing regimens over oxaliplatin alone. The current study demonstrates that the addition of bevacizumab to oxaliplatin-based chemotherapy does not worsen outcomes after hepatectomy. In fact, by reducing sinusoidal liver injury, bevacizumab may promote liver regeneration, which might otherwise be impaired by hepatic sinusoidal dilation.
In addition, the duration of pre-PVE chemotherapy did not affect liver regeneration and postoperative outcome in the present study. This is in contrast with previous studies showing higher postoperative complication rates related to the duration of chemotherapy Karoui et al. 30 reported higher morbidity among patients who received six or more cycles compared with fewer than six cycles. Similarly, in the study by Aloia et al., 31 patients who received >12 courses of chemotherapy (5-fluorouracil with or without oxaliplatin) were predisposed to reoperation and longer hospitalization than patients who received £12 courses. In the current study, for instance, one patient had a high DH (15%) and an uneventful postoperative recovery despite prolonged chemotherapy with 11 cycles including bevacizumab. Our results likely did not show a correlation between duration of preoperative chemotherapy and postoperative outcome because of the small number of patients.
In conclusion, neoadjuvant chemotherapy with bevacizumab does not impair the liver regeneration after PVE and allows an adequate DH of the FLR. Patients with CLM can safely undergo chemotherapy with bevacizumab and PVE before liver resection.
